Sat.Jan 02, 2021 - Fri.Jan 08, 2021

article thumbnail

UK left trailing as EU quickly approves Moderna’s COVID-19 vaccine

pharmaphorum

The European Union has approved the coronavirus vaccine from Moderna, leaving the UK trailing because of changes to post-Brexit drug approval rules. With the UK reeling from one of the worst outbreaks of the disease, it’s a worrying situation for one of the countries worst hit by the pandemic that is relying on vaccines to bring the virus under control.

Vaccines 141
article thumbnail

5 Trends That Will Shape Pharma Marketing in 2021

Pharma Marketing Network

Throughout the year 2020, pharma marketers were forced to explore new strategies in order to keep up with the many evolving trends. Pharma marketers have quickly learned how to adapt to these trends and are prepared to take on new opportunities in 2021. Five trends that will shape the pharma marketing industry in 2021 include media and tech, location independence, relationships despite digital congestion, questioning systems and doubt in institutions, and feelings around trust and wellness.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Flucloxacillin vs Amoxicillin: 2 most POPULAR antibiotics

Druggist

Amoxicillin is the most commonly prescribed antibiotic in the UK, with over 6 mln prescriptions issued in the last 12 months. Flucloxacillin is less popular with around 3.6 mln prescriptions issued during the same time (OpenPrescribing.net, 2021). Both antibiotics’ distinct popularity comes mainly from different recommended use in the treatment of bacterial infections, even though both drugs belong to the same class of antibiotics: penicillins.

98
article thumbnail

People on the Move: January 2021

Outsourcing Pharma

Industry organizations with hires, promotions, acquisitions and other news to share this month include Parexel, Novartis, WCG, Idifarma and more top firms.

96
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Pfizer/BioNTech vaccine may work against new virus mutation, scientists say

pharmaphorum

The Pfizer/BioNTech vaccine appears to work against an important mutation in the new coronavirus variants causing havoc in the UK and South Africa, according to research from the drugs giant. Findings of the lab study posted online have not yet been peer reviewed but provide some reassurance for countries like the UK, which are relying on vaccines to bring the pandemic under control.

Vaccines 123
article thumbnail

Choosing a Baby Formula

Pharma Mirror

Infant nutrition, outside of breastfeeding, has become a hot topic recently. Families are taking a hard look at how baby formulas’ ingredients impact their children’s health and development. Concerns and Contamination Every day American parents and caregivers reach for over-the-counter baby formulas and are surprised to find chemicals, additives, and other ingredients that are known to cause health concerns.

FDA 52

More Trending

article thumbnail

Pharmaceutical firms warming up to outsourcing: ReAgent

Outsourcing Pharma

A leader from the chemical manufacturing firm notes pharma companies are showing increased interest in contracting out their manufacturing functions.

73
article thumbnail

Why cell therapy manufacture is a team sport

pharmaphorum

Louis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that sits behind the process of individualised cell therapy – and why team culture makes it work. This thought leadership series has been paid and developed by Kite, a Gilead Company. In 2018, we were preparing to build a European facility to produce individualised cell therapies for the treatment of cancer.

Hospitals 119
article thumbnail

CRUK scientists develop drug that targets KRAS pathways

Pharma Times

KRAS mutations are found in several hard-to-treat cancers

64
article thumbnail

GLP-1 Agonists And The Prescribing Cascade

Med Ed 101

The GLP-1 Agonists have grown significantly in their popularity and there are good reasons for that increase in use. They promote weight loss which is a big problem in the majority of our type 2 diabetes patients. In addition to this benefit, they have also been shown to positively affect cardiovascular outcomes. With any medication, […]. The post GLP-1 Agonists And The Prescribing Cascade appeared first on Med Ed 101.

40
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

First FDA COVID-19 update of 2021

Outsourcing Pharma

As healthcare providers and other high-priority patients begin receiving the vaccines, the agency continues to act to help the national pandemic response.

FDA 58
article thumbnail

Pfizer drops the blue pill, kicks off 2021 with new DNA logo

pharmaphorum

Pharma companies are always talking about moving ‘beyond the pill’, and Pfizer’s new brand identity embodies that – it’s decades old pill-like logo has been replaced with a DNA double helix that it says reflects its commitment to breakthrough science. The logo – which retains the company’s traditional blue colour scheme – has been more than 18 months in the making and according to the company it is “unlocking the pill to reveal Pfizer’s DNA: the power of science.”.

Vaccines 116
article thumbnail

University of Birmingham researchers develop rapid COVID-19 RNA test

Pharma Times

Test can give accurate results in under five minutes, according to researchers

50
article thumbnail

Oxford BioTherapeutics to research cell therapies for Gilead’s Kite

pharmaphorum

Gilead Sciences’ Kite unit has teamed up with the UK’s Oxford BioTherapeutics (OBT) to develop a new clutch of cell therapy products for solid tumours and blood cancers. The partnership covers up to five oncology targets identified by OBT using its discovery platform, and the UK firm will try to develop antibodies against them. Kite and Gilead will then develop and commercialise therapies based on these targets or antibodies.

104
104
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

True patient-focused research through decentralised and hybrid trials

pharmaphorum

How can pharma improve the patient-centricity of its trials during COVID-19 and beyond? Experts from across the sector give their thoughts on the key approaches and technologies that are driving patient engagement forward. With COVID-19 presenting new barriers to running and recruiting for clinical trials, making studies patient-centric is more important now than ever before.

105
105
article thumbnail

EMA will use Panalgo software for real-world data analytics

pharmaphorum

Six months after rebranding from BHE, Panalgo has won a contract to supply the European Medicines Agency (EMA) with its IHD data analytics platform, pledging to streamline its public health efforts. IHD – or Instant Health Data – will be used by the EMA to carry out data analyses and examine medicinal product utilisation, answer questions about safety and efficacy, and understand how treatments perform in real-world settings, said the Boston, US-based company.

105
105
article thumbnail

IL-6 drugs do work in COVID-19, says UK, as it plans NHS use

pharmaphorum

New data means that IL-6 drugs from Roche and Sanofi that had been all-but written off as coronavirus therapies will now be offered routinely to COVID-19 patients in intensive care in the UK. The renaissance of the two therapies comes on the back of the REMAP-CAP trial, which found that the IL-6 inhibitors RoActemra (tocilizumab) and Kevzara (sarilumab) reduced the relative risk of death by 24% when administered to COVID-19 patients within 24 hours of entering intensive care, and reduce the tim

Hospitals 105
article thumbnail

How Big Data will accelerate the future of digital medicine in 2021

pharmaphorum

The pandemic has shed light on inefficiencies in healthcare systems, and provided an opportunity to adjust how we manage care in the future. Jennifer Haas, executive vice president of Noteworth, shares her 2021 predictions surrounding the future of telehealth and big data. . Healthcare providers are grappling with the task of scaling digital care delivery operations for ambulatory patients in response to the cost dynamics of effectively treating large populations with limited resources, especial

Hospitals 111
article thumbnail

Bayer joins the COVID-19 vaccine push, backing CureVac shot

pharmaphorum

Shortly after launching large-scale trials of its COVID-19 vaccine candidate, CureVac has the partner it will need to roll the shot out at scale if it works as hoped. Bayer has joined forces with the German biotech to support the development and supply of CVnCoV, an mRNA candidate using a similar technology to the Pfizer/BioNTech and Moderna jabs, with the drugmaker saying it will help CureVac produce “several hundred million doses” CureVac has been working steadily on CVnCoV over the last

Vaccines 103
article thumbnail

AbbVie scores crucial phase 3 wins with Humira follow-up Skyrizi

pharmaphorum

AbbVie is in a race against time as US patent expiry of its Humira inflammatory diseases blockbuster looms in 2023 – but it just scored two crucial phase 3 trial victories that could help rebuild sales when cheaper biosimilars flood the market in two years’ time. The company’s follow-up drug Skyrizi is a key plank in AbbVie’s strategy to negotiate the $20 billion patent cliff from Humira, which has already seen sales decline outside of the US where it has already lost protection from cheaper com

97
article thumbnail

Using Define-XML for Dataset Design

pharmaphorum

In the past, sponsors submitting to FDA were required to submit a PDF describing their submission datasets. As we all know PDF is great for viewing on-screen or printing, but the information inside can’t be interpreted by a computer. Enter CDISC’s Define-XML model. Define-XML standardizes how to describe datasets in a machine-readable manner.

FDA 98
article thumbnail

Roche set to file ophthalmology drug faricimab in DME

pharmaphorum

Roche looks set to mount a challenge to Bayer’s ophthalmology drug Eylea in 2021 after its faricimab antibody showed comparable results in diabetic macular oedema (DME) but with half the injections, in twin phase 3 studies. While Eylea (aflibercept) is taken in doses eight weeks apart, results from the YOSEMITE and RHINE studies showed faricimab produces a similar effect but with a 16-week dosing regimen.

98
article thumbnail

COVID-19 and the digital pharma marketing revolution

pharmaphorum

The global pandemic has caused pharma companies to invest in digital marketing, as healthcare systems across the world adapt to strict lockdown rules. Once the global emergency ends, this trend will continue, argues pharmaphorum’s Richard Staines. The global outbreak of COVID-19 has forced businesses to radically change their way of working. Healthcare companies have been in the vanguard of this change, with an enormous rise in the use of telehealth and all forms of digital communications.

article thumbnail

Clene goes public with gold-based neurology nanotechnology

pharmaphorum

Biotech Clene Nanomedicine has gone public with a mission to use nanotherapeutics that will use gold to treat devastating neurological diseases including Parkinson’s disease. Over the Christmas period Clene closed a reverse merger with Tottenham Acquisition I Limited, allowing shares to be publicly traded on the Nasdaq stock exchange. The US-based company says it aims to revolutionise treatment of diseases including multiple sclerosis and amyotrophic lateral sclerosis with a new class of drugs t

75
article thumbnail

Ex-Resolute co-founder Blackburn starts hybrid agency Certain Health

pharmaphorum

Former joint founder and owner of Resolute Communications and Real Science Paul Blackburn has launched a new hybrid agency, Certain Health. Blackburn made the move after Resolute and Real Science were absorbed into Publicis Langland. The company said its hybrid model has the benefits of both the traditional and virtual agency models, with expertise in health PR, medical education and the creative space.

article thumbnail

Amazon’s health venture Haven to cease trading

pharmaphorum

Haven, the healthcare venture launched by Amazon, Berkshire Hathaway and JP Morgan Chase is to cease trading next month after failing to achieve its goal of pushing down health insurance costs for US workers. The joint venture had been billed by many as Amazon’s big move into healthcare when it was launched three years ago with great fanfare. But since then there has been little news from the secretive venture sparked by an idea from JPMorgan CEO Jamie Dillion, with support from Amazon’s Jeff Be

article thumbnail

Blockchain app used to ensure passenger safety during pandemic

pharmaphorum

There are hopes that a new app based on blockchain technology will allow safe international travel via Singapore’s Changi Airport, which verifies passengers’ COVID-19 status before boarding planes. Developed by health and security provider International SOS and AOKPass, the app was first used to provide a digitally verifiable COVID-19 heath certificate for entrance to Singapore on 21st December.

69
article thumbnail

Moderna’s COVID-19 vaccine is third approved in UK

pharmaphorum

The UK has approved the Moderna coronavirus vaccine, hard on the heels of its go-ahead in Europe, although supplies are not expected to arrive for several weeks. Moderna’s mRNA-1273 is the third COVID-19 vaccine to be approved for use by the Medicines and Healthcare products Regulatory Agency (MHRA) and is the second mRNA vaccine after Pfizer/BioNTech’s Comirnaty, which got the nod in December.

article thumbnail

NHS Digital awards £8m COVID record contract to X-lab

pharmaphorum

The UK government agency NHS Digital has awarded an £8m digital system that processes coronavirus test results to healthcare software specialist X-Lab without competition. According to a tender document , the “extreme urgency brought about by the COVID-19 pandemic situation” justified the decision not to open up the contract to competition. The document added that the technical demands for the project mean that X-Labs is the only provider capable of fulfilling the contract.

article thumbnail

Medical Writing Landscape Advancement Summit | Virtual

pharmaphorum

The Lincoln Health Network is excited to announce our 2nd Medical Writing Landscape Advancement Summit , March 3-4, 2021. Join us virtually, on the LHN virtual event platform to improve your medical writing strategies by understanding evolving regulatory protocols and submission guidelines, and learn how to improve quality and content optimizations.

article thumbnail

Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit

pharmaphorum

Two years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a joint project to find new, gene-silencing drugs for liver-related cardiometabolic diseases. Danish drugmaker Novo Nordisk signed a deal with the US biotech in 2019 valued at up to $675.5 million – including $175 million upfront and an equity investment of $50 million – to find multiple RNA interference (RNAi) candidates for diseases like non-alcoholic steatohepatitis (NASH) and type 2 dia

FDA 60
article thumbnail

UK promises ‘uplift’ in COVID-19 vaccinations as crisis deepens

pharmaphorum

The UK government has promised a “massive uplift” in the number of coronavirus vaccinations carried out this week, while conceding a target of 13.9 million jabs offered by the end of February will be “challenging”. As the number of daily recorded cases in the country exceeded 60,000 for the first time, vaccine minister Nadhim Zahawi told BBC Radio 4’s today programme: “My absolute focus is to get to 13.9 million…offered a vaccine by the middle of February.

article thumbnail

Further, Trustedoctor merge to provide ‘borderless’ healthcare

pharmaphorum

Private medical insurance company Further Group has ramped up its presence in digital healthcare by merging with Trustedoctor, a startup that puts patients in contact with medical professionals. Further – which was rebranded from BDU International last year – specialises in providing cross-border health insurance to people across Europe, the Middle East, Africa and Asia, and according to CEO Frank Ahedo aims to provide people with access to healthcare “no matter what the location or cost.”.

article thumbnail

Angelini and Arvelle create neurology player with $960m merger

pharmaphorum

There’s a new player in the neurology and mental health drugs market after Italy’s Angelini Pharma merged with Switzerland’s Arvelle Therapeutics in a deal worth up to $960 million based around the anti-seizure drug cenobamate. Angelini is an international pharma company that is part of the privately-owned Italian Angelini Group, while Arvelle is focused on bringing innovative treatments to patients suffering from CNS disorders.